233 related articles for article (PubMed ID: 33802801)
21. Targeting Notch1 and proteasome as an effective strategy to suppress T-cell lymphoproliferative neoplasms.
Yang L; Zhang S; George SK; Teng R; You X; Xu M; Liu H; Sun X; Amin HM; Shi W
Oncotarget; 2015 Jun; 6(17):14953-69. PubMed ID: 25879451
[TBL] [Abstract][Full Text] [Related]
22. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
[TBL] [Abstract][Full Text] [Related]
23. Proteasome inhibition and mechanism of resistance to a synthetic, library-based hexapeptide.
Oerlemans R; Berkers CR; Assaraf YG; Scheffer GL; Peters GJ; Verbrugge SE; Cloos J; Slootstra J; Meloen RH; Shoemaker RH; Dijkmans BAC; Scheper RJ; Ovaa H; Jansen G
Invest New Drugs; 2018 Oct; 36(5):797-809. PubMed ID: 29442210
[TBL] [Abstract][Full Text] [Related]
24. [Mechanism of action and determinants of sensitivity to the proteasome inhibitor bortezomib in multiple myeloma therapy].
Ri M
Rinsho Ketsueki; 2016 May; 57(5):537-45. PubMed ID: 27263777
[TBL] [Abstract][Full Text] [Related]
25. Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC-Dependent Cell Death in T-cell and Hodgkin Lymphoma.
Ravi D; Beheshti A; Abermil N; Passero F; Sharma J; Coyle M; Kritharis A; Kandela I; Hlatky L; Sitkovsky MV; Mazar A; Gartenhaus RB; Evens AM
Cancer Res; 2016 Jun; 76(11):3319-31. PubMed ID: 26988986
[TBL] [Abstract][Full Text] [Related]
26. Profiling human protein degradome delineates cellular responses to proteasomal inhibition and reveals a feedback mechanism in regulating proteasome homeostasis.
Yu T; Tao Y; Yang M; Chen P; Gao X; Zhang Y; Zhang T; Chen Z; Hou J; Zhang Y; Ruan K; Wang H; Hu R
Cell Res; 2014 Oct; 24(10):1214-30. PubMed ID: 25223703
[TBL] [Abstract][Full Text] [Related]
27. Ixazomib for Relapsed or Refractory Multiple Myeloma: Review from an Evidence Review Group on a NICE Single Technology Appraisal.
Armoiry X; Connock M; Tsertsvadze A; Cummins E; Melendez-Torres GJ; Royle P; Clarke A
Pharmacoeconomics; 2018 Sep; 36(9):1073-1081. PubMed ID: 29582405
[TBL] [Abstract][Full Text] [Related]
28. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.
Colado E; Alvarez-Fernández S; Maiso P; Martín-Sánchez J; Vidriales MB; Garayoa M; Ocio EM; Montero JC; Pandiella A; San Miguel JF
Haematologica; 2008 Jan; 93(1):57-66. PubMed ID: 18166786
[TBL] [Abstract][Full Text] [Related]
29. Targeting autophagy increases the efficacy of proteasome inhibitor treatment in multiple myeloma by induction of apoptosis and activation of JNK.
Salimi A; Schroeder KM; Schemionek-Reinders M; Vieri M; Maletzke S; Gezer D; Masouleh BK; Appelmann I
BMC Cancer; 2022 Jul; 22(1):735. PubMed ID: 35790913
[TBL] [Abstract][Full Text] [Related]
30. Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases.
Xi J; Zhuang R; Kong L; He R; Zhu H; Zhang J
Eur J Med Chem; 2019 Nov; 182():111646. PubMed ID: 31521028
[TBL] [Abstract][Full Text] [Related]
31. MLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy-sensitive or rituximab-chemotherapy-resistant B-cell lymphoma preclinical models.
Gu JJ; Hernandez-Ilizaliturri FJ; Mavis C; Czuczman NM; Deeb G; Gibbs J; Skitzki JJ; Patil R; Czuczman MS
Anticancer Drugs; 2013 Nov; 24(10):1030-8. PubMed ID: 23995855
[TBL] [Abstract][Full Text] [Related]
32. Ixazomib - the first oral proteasome inhibitor.
Xie J; Wan N; Liang Z; Zhang T; Jiang J
Leuk Lymphoma; 2019 Mar; 60(3):610-618. PubMed ID: 30614337
[TBL] [Abstract][Full Text] [Related]
33. Ritonavir, nelfinavir, saquinavir and lopinavir induce proteotoxic stress in acute myeloid leukemia cells and sensitize them for proteasome inhibitor treatment at low micromolar drug concentrations.
Kraus M; Müller-Ide H; Rückrich T; Bader J; Overkleeft H; Driessen C
Leuk Res; 2014 Mar; 38(3):383-92. PubMed ID: 24418752
[TBL] [Abstract][Full Text] [Related]
34. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.
Chauhan D; Tian Z; Zhou B; Kuhn D; Orlowski R; Raje N; Richardson P; Anderson KC
Clin Cancer Res; 2011 Aug; 17(16):5311-21. PubMed ID: 21724551
[TBL] [Abstract][Full Text] [Related]
35. The γ-secretase inhibitor GSI-I interacts synergistically with the proteasome inhibitor bortezomib to induce ALK+ anaplastic large cell lymphoma cell apoptosis.
Dang Q; Chen L; Xu M; You X; Zhou H; Zhang Y; Shi W
Cell Signal; 2019 Jul; 59():76-84. PubMed ID: 30878517
[TBL] [Abstract][Full Text] [Related]
36. Profound activity of the anti-cancer drug bortezomib against Echinococcus multilocularis metacestodes identifies the proteasome as a novel drug target for cestodes.
Stadelmann B; Aeschbacher D; Huber C; Spiliotis M; Müller J; Hemphill A
PLoS Negl Trop Dis; 2014 Dec; 8(12):e3352. PubMed ID: 25474446
[TBL] [Abstract][Full Text] [Related]
37. Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis.
Verbrugge SE; Assaraf YG; Dijkmans BA; Scheffer GL; Al M; den Uyl D; Oerlemans R; Chan ET; Kirk CJ; Peters GJ; van der Heijden JW; de Gruijl TD; Scheper RJ; Jansen G
J Pharmacol Exp Ther; 2012 Apr; 341(1):174-82. PubMed ID: 22235146
[TBL] [Abstract][Full Text] [Related]
38. The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma.
Gu JJ; Hernandez-Ilizaliturri FJ; Kaufman GP; Czuczman NM; Mavis C; Skitzki JJ; Czuczman MS
Br J Haematol; 2013 Sep; 162(5):657-69. PubMed ID: 23826755
[TBL] [Abstract][Full Text] [Related]
39. Rational drug combination design in patient-derived avatars reveals effective inhibition of hepatocellular carcinoma with proteasome and CDK inhibitors.
Lim JJ; Hooi L; Dan YY; Bonney GK; Zhou L; Chow PK; Chee CE; Toh TB; Chow EK
J Exp Clin Cancer Res; 2022 Aug; 41(1):249. PubMed ID: 35971164
[TBL] [Abstract][Full Text] [Related]
40. Discovery of Peptide Boronate Derivatives as Histone Deacetylase and Proteasome Dual Inhibitors for Overcoming Bortezomib Resistance of Multiple Myeloma.
Zhou Y; Liu X; Xue J; Liu L; Liang T; Li W; Yang X; Hou X; Fang H
J Med Chem; 2020 May; 63(9):4701-4715. PubMed ID: 32267687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
